StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Castle Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Castle Biosciences's total debt was $10.08M at Sep 30, 2026. For fiscal 2025 it was $10.06M, up 0.3% from the year before. The highest annual figure on record is $25.12M in fiscal 2019.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.06M+0.3%
FY2024Dec 31, 2024$10.02M–
FY2023Dec 31, 2023$0–
FY2020Dec 31, 2020$0-100.0%
FY2019Dec 31, 2019$25.12M+2.5%
FY2018Dec 31, 2018$24.50M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$10.08M+0.3%
Q2 FY2026Jun 30, 2026$10.08M+0.3%
Q1 FY2026Mar 31, 2026$10.07M+0.3%
Q4 FY2025Dec 31, 2025$10.06M+0.3%
Q3 FY2025Sep 30, 2025$10.05M+0.3%
Q2 FY2025Jun 30, 2025$10.04M+0.3%
Q1 FY2025Mar 31, 2025$10.03M+0.3%
Q4 FY2024Dec 31, 2024$10.02M–
Q3 FY2024Sep 30, 2024$10.02M–
Q2 FY2024Jun 30, 2024$10.01M-55.4%
Q1 FY2024Mar 31, 2024$10.00M-59.6%
Q4 FY2023Dec 31, 2023$0-100.0%
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2020Sep 30, 2020$22.46M-9.8%
Q2 FY2020Jun 30, 2020$24.74M-15.0%
Q1 FY2020Mar 31, 2020$25.35M+3.5%
Q4 FY2019Dec 31, 2019$25.12M–
Q3 FY2019Sep 30, 2019$24.90M–
Q2 FY2019Jun 30, 2019$29.12M–
Q4 FY2018Dec 31, 2018$24.50M–

More Castle Biosciences figures

See a number that looks wrong?